In 2001, Delphi Genetics was launched as an IBMM spin-off to develop original genetic engineering solutions. Its main sectors of activity are the production of recombinant DNA and bespoke DNA assemblies.
Delphi Genetics continues to work in collaboration with IBMM teams, researching new genetic engineering solutions. This cooperation has given light to technologies based on the understandings gained of how bacterial poison and antidote genes work. Today, Delphi Genetics holds a worldwide licence for the use of the patents resulting from its research.